Profile: BioSante Pharmaceuticals, Inc. (BPAX.O)

Biosante Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company primary products include gel formulations of testosterone and estradiol. It is also engaged in the development of its calcium phosphate nanotechnology (CaP), primarily for aesthetic medicine, vaccines and drug delivery. The Company’s principal products include LibiGel, Bio-T-Gel and Pill-Plus. The Company’s CaP products in development include BioLook, BioVant, BioOral and BioAir. In October 2009, BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. announced the completion of the merger of Cell Genesys, Inc. with and into BioSante Pharmaceuticals, Inc., with BioSante Pharmaceuticals, Inc. as the surviving company. Pursuant to the merger, BioSante Pharmaceuticals, Inc. has acquired all of the outstanding shares of Cell Genesys, Inc.

LibiGel

LibiGel is a once daily transdermal testosterone gel designed to treat female sexual dysfunction, specifically hypoactive sexual desire disorder in menopausal women. LibiGel has completed a Phase II clinical trial, and its three Phase III safety and efficacy clinical trials are underway and enrolling women. As of December 31, 2008, three LibiGel Phase III trials are underway: two LibiGel Phase III safety and efficacy clinical trials and one Phase III cardiovascular and breast cancer safety study. Both Phase III safety and efficacy trials are double-blind, placebo-controlled trials. The Phase III safety study is a randomized, double-blind, placebo-controlled and multi-center, cardiovascular events.

Elestrin

The Company’s estrogen formulated gel product, Elestrin, is a once daily gel that delivers estrogen without the skin irritation associated with, and the physical presence of, transdermal patches. In December 2006, the Company received United States Food & Drug Administration (FDA) approval for the marketing of Elestrin in the United States. Elestrin is indicated for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause.

Other Hormone Therapy Products

The Company’s hormone therapy products include Bio-T-Gel and the Pill-Plus. The Company has entered into several license or sublicense agreements covering some of its hormone therapy products, including a development and license agreement with Teva Pharmaceuticals USA, Inc., pursuant to which Teva USA is developing its male testosterone gel, Bio-T-Gel, for the United States market.

In September 2008, the Company announced the results of clinical work on its Pill-Plus triple hormone therapy oral contraceptive. The Pill-Plus adds a third hormone, an androgen, to the normal two hormone (estrogen and progestogen) oral contraceptive to prevent androgen deficiency. The Pill-Plus is designed to improve the condition known as female sexual dysfunction in oral contraceptive users.

The Company competes with Upsher-Smith Laboratories, Inc., Noven Pharmaceuticals, Inc., Wyeth, Auxilium Pharmaceuticals, Inc., Ascend Therapeutics, Inc., Watson Pharmaceuticals, Inc., KV Pharmaceutical Co., Solvay Pharmaceuticals, Inc., GlaxoSmithKline plc, Sanofi-aventis and Merck & Co., Inc.